Xinjiang Baihuacun Co Ltd (600721) Fair Value & Analysis
Consumer Cyclical · CN · Market cap 4.1B CNY
Structural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.
Strengths
Risks
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 13 days ago
Share price +116.6% over the past month.
A solid business, but trading 742% above our fair value.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (¥2.25). The favourable scenario is already priced in.
- Solid but not exceptional quality (58/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ¥3.09 – ¥15.16 · fair‑value band ¥1.52 – ¥2.25 · the ¥15.16 price screens above the ¥1.80 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 3 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Xinjiang Baihuacun Co Ltd (600721) currently trades at ¥15.16, while our model-based Fair Value estimate is ¥1.80, implying the stock looks roughly 88.1% overvalued today. The Quality Score stands at 58/100 (solid quality), in the Consumer Cyclical sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Xinjiang Baihuacun Co Ltd generated revenue of 359M CNY at a net margin of 7.4%. Revenue declined 30.7% year over year. It earns a return on equity of 3.4%. The balance sheet holds a net cash position of 296M CNY. Fundamentals as of Aug 13, 2026
Our scenario range runs from ¥1.52 (bear case) to ¥2.25 (bull case); at ¥15.16, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades near its 52-week high and 119% above its 52-week low, currently above its 200-day average. For context, the median of 10 Consumer Cyclical peers we cover trades at -48% fair-value upside, at -88%, 600721 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: DCF Models (¥2.67) versus Dividend Discount (¥0.0100). Highest evidence: Growth DCF (80).
Notify me when 600721 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 57 · Market factors (momentum, volatility) 71
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd engages in pharmaceutical research and development, clinical trials, biomedicine, commercial properties, and other businesses.
Full company description
Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd engages in pharmaceutical research and development, clinical trials, biomedicine, commercial properties, and other businesses. It also offers comprehensive contract research organization (CRO) solutions, including one-stop, full-process services for drug R&D, such as Phase I to IV clinical trials, bioequivalence and pharmacokinetics testing, medical science services, R&D project consulting, data management and statistical services, and third-party testing, which covers bioanalytical testing, packaging material compatibility, compound structure confirmation, quality studies, and base toxic impurity analysis. The company was formerly known as Xinjiang Baihuacun Co., Ltd. and changed its name to Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd in July 2021. Xinjiang Bai Hua Cun Pharma Tech Co.,Ltd was founded in 1959 and is based in Urumqi, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Xinjiang Baihuacun Co Ltd reported revenue of ¥388M in FY2025 versus ¥281M in FY2021, a compound +8.3%/yr. Reported net income was ¥40.7M in FY2025, compounding −9.2%/yr from FY2021.
600721 screens 88% overvalued. Compare with McDonald's Corporation →
Peer Group
Restaurants · 231 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Restaurants median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Restaurants stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McDonald's Corporation MCD | $265.53 | $149.03 | -44% |
| Starbucks Corporation SBUX | $108.49 | $35.83 | -67% |
| Chipotle Mexican Grill, Inc CMG | $34.66 | $17.92 | -48% |
| Yum! Brands, Inc YUM | $150.34 | $58.17 | -61% |
| Restaurant Brands International Inc QSR | C$104.50 | C$36.37 | -65% |
| Darden Restaurants, Inc DRI | $218.86 | $173.68 | -21% |
| Yum China Holdings YUMC | $47.90 | $54.27 | +13% |
| Texas Roadhouse, Inc TXRH | $214.28 | $104.89 | -51% |
| Dutch Bros Inc BROS | $51.02 | $12.80 | -75% |
| Domino's Pizza, Inc DPZ | $336.52 | $227.31 | -32% |
Compare Xinjiang Baihuacun Co Ltd with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Consumer Cyclical stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Xinjiang Baihuacun Co Ltd (600721) overvalued or undervalued?
What is the fair value of 600721?
What is the quality score of 600721?
What is the revenue of Xinjiang Baihuacun Co Ltd (600721)?
What is the net profit margin of 600721?
Does Xinjiang Baihuacun Co Ltd pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Xinjiang Baihuacun Co Ltd and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.